Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306

Rhea-AI Summary

Repare Therapeutics Inc. (Nasdaq: RPTX) announced that data from Phase I/II trials of camonsertib in combination with PARP inhibitors has been selected for presentation at the 2023 AACR Annual Meeting in Orlando, Florida, from April 14-19, 2023. The presentation will highlight safety and efficacy results in patients with solid tumors with DNA damage response alterations, featuring Dr. Timothy Yap. Additionally, two poster presentations will characterize genomic features in ovarian and uterine cancers. Repare's SNIPRx® platform enables the development of precision oncology therapies targeting genomic instability, showcasing its commitment to innovative cancer treatment.

Positive

• Data from Phase I/II trials of camonsertib selected for a significant clinical plenary session at AACR 2023.
• Presentation will focus on promising safety and efficacy results of treatment combinations.
• SNIPRx® platform enhances Repare's capability to develop targeted cancer therapies.

Negative

• None.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida. An AACR assigned discussant of the presentation will interpret the data in this plenary session. Two poster presentations for RP-6306, a first-in-class, oral PKMYT1 inhibitor, will also be introduced in the Clinical Research session.

Details for the presentations are as follows:

Title: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations
Presenter: Dr. Timothy Yap
Session Category: Clinical Trials Plenary Session
Session Title: Novel Biomarker-driven Molecularly Targeted Therapy Trials
Date and Time: Tuesday Apr 18, 2023 11:15 AM - 11:30 AM
Published Abstract Number: 23-LB-9625-AACR

Title: Characterization of CCNE1 amplifications and associated genomic features in ovarian and uterine cancers
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkers of Therapeutic Benefit 5
Date and Time: Tuesday Apr 18, 2023 1:30 PM - 5:00 PM
Location: Poster Section 37
Poster Board Number: 19
Published Abstract Number: 5469

Title: Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkers of Therapeutic Benefit 2
Date and Time: Monday Apr 17, 2023 9:00 AM - 12:30 PM
Location: Poster Section 39
Poster Board Number: 6
Published Abstract Number: 2132

About Repare Therapeutics’ SNIPRx® Platform

Repare’s SNIPRx® platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; a preclinical Polθ inhibitor program; as well as several additional, undisclosed preclinical programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005911/en/

Repare Contact:



Robin Garner

Executive Director and Head of Investor Relations

Repare Therapeutics Inc.

investor@reparerx.com



Investors:



Matthew DeYoung

Argot Partners

repare@argotpartners.com



Media:



David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Repare Therapeutics Inc.

FAQ

What is the significance of Repare Therapeutics' data presentation at the 2023 AACR Annual Meeting?

Repare Therapeutics' data presentation is significant as it showcases promising results from Phase I/II trials of camonsertib combined with PARP inhibitors, highlighting the safety and efficacy of this treatment in patients with specific cancer types.

When will Repare Therapeutics present its findings at the AACR Annual Meeting?

Repare Therapeutics will present its findings on April 18, 2023, during the clinical trials plenary session.

What role does the SNIPRx® platform play in Repare Therapeutics' research?

The SNIPRx® platform is crucial for identifying novel and known gene pairs for targeted cancer therapies, allowing Repare to develop precision treatments based on the genetic profiles of tumors.

Where can I find more information about Repare Therapeutics and their clinical trials?

More information about Repare Therapeutics and their clinical trials can be found on their official website at reparerx.com.

What are the key dates for Repare Therapeutics' presentations during the AACR 2023?

Key dates include April 18, 2023, for the clinical plenary session presentation and additional poster presentations on the same day.